The Value of Troponin as a Biomarker of Chemotherapy-Induced Cardiotoxicity
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Value of Troponin as a Biomarker of Chemotherapy-Induced Cardiotoxicity
Authors
Keywords
-
Journal
Life-Basel
Volume 12, Issue 8, Pages 1183
Publisher
MDPI AG
Online
2022-08-04
DOI
10.3390/life12081183
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Early detection of anthracycline‐ and trastuzumab‐induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters
- (2022) Belén Díaz‐Antón et al. ESC Heart Failure
- How to early identify anthracycline-induced cardiotoxicity and reduce its clinical impact in everyday practice
- (2021) Gennaro Carmine Semeraro et al. Kardiologia Polska
- Assessment and Management of Cardiotoxicity in Hematologic Malignancies
- (2021) Anca Bojan et al. DISEASE MARKERS
- Cardiac and cardiometabolic phenotyping of trastuzumab-mediated cardiotoxicity: a secondary analysis of the MANTICORE trial
- (2021) Amy A Kirkham et al. European Heart Journal-Cardiovascular Pharmacotherapy
- Circulating Biomarkers for Cardiotoxicity Risk Prediction
- (2021) Fei Fei Gong et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies
- (2021) Naomi Dempsey et al. BREAST CANCER RESEARCH AND TREATMENT
- Assessment of Prognostic Value of High-Sensitivity Cardiac Troponin T for Early Prediction of Chemoradiation Therapy-Induced Cardiotoxicity in Patients with Non-Small Cell Lung Cancer: A Secondary Analysis of a Prospective Randomized Trial
- (2021) Ting Xu et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Clinical Approach to Cardiovascular Toxicity of Oral Antineoplastic Agents
- (2021) Vijay U. Rao et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement
- (2021) Joerg Herrmann et al. EUROPEAN HEART JOURNAL
- Role of Cardiac Biomarkers in Cancer Patients
- (2021) Gennaro Carmine Semeraro et al. Cancers
- Advances in Biomarkers for Detecting Early Cancer Treatment-Related Cardiac Dysfunction
- (2021) Huiyu Xiao et al. Frontiers in Cardiovascular Medicine
- Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction
- (2020) Biniyam G. Demissei et al. Journal of the American Heart Association
- A Prospective Study About Trastuzumab-induced Cardiotoxicity in HER2-positive Breast Cancer
- (2020) Wala Ben Kridis et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
- (2020) Joerg Herrmann Nature Reviews Cardiology
- Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice
- (2020) Nathalie I. Bouwer et al. BREAST
- Evidence on clinical relevance of cardiovascular risk evaluation in the general population using cardio-specific biomarkers
- (2020) Aldo Clerico et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- The role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a Position statement on behalf of the Heart Failure Association ( HFA ), the European Association of Cardiovascular Imaging ( EACVI ) and the Cardio‐Oncology Council of the European Society of Cardiology ( ESC )
- (2020) Jelena Čelutkienė et al. EUROPEAN JOURNAL OF HEART FAILURE
- Echocardiography and biomarkers for the diagnosis of cardiotoxicity
- (2020) Dominik Berliner et al. HERZ
- The Role of Biomarkers in Cardio-Oncology
- (2020) Kajaluxy Ananthan et al. Journal of Cardiovascular Translational Research
- Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio‐Oncology Study Group of the Heart Failure Association and the Cardio‐Oncology Council of the European Society of Cardiology
- (2020) Radek Pudil et al. EUROPEAN JOURNAL OF HEART FAILURE
- Identification and Management of Immune Checkpoint Inhibitor–Related Myocarditis: Use Troponin Wisely
- (2019) Paolo Spallarossa et al. JOURNAL OF CLINICAL ONCOLOGY
- Myocarditis in the Setting of Cancer Therapeutics
- (2019) Marc P. Bonaca et al. CIRCULATION
- Cardiotoxicity of Immune Therapy
- (2019) Sarju Ganatra et al. CARDIOLOGY CLINICS
- Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta‐analysis
- (2019) Lars Michel et al. EUROPEAN JOURNAL OF HEART FAILURE
- Possible mechanisms behind cardiac troponin elevations
- (2018) Ola Hammarsten et al. BIOMARKERS
- Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial
- (2018) Daniela Cardinale et al. EUROPEAN JOURNAL OF CANCER
- Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens
- (2018) Aurelia H. M. de Vries Schultink et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
- (2018) Syed S. Mahmood et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Biomarker Discovery in Cardio-Oncology
- (2018) Anita Vohra et al. Current Cardiology Reports
- Activity and outcomes of a cardio-oncology service in the United Kingdom-a five-year experience
- (2018) Nilesh Pareek et al. EUROPEAN JOURNAL OF HEART FAILURE
- Anthracycline Therapy Is Associated With Cardiomyocyte Atrophy and Preclinical Manifestations of Heart Disease
- (2018) Thiago Ferreira de Souza et al. JACC-Cardiovascular Imaging
- Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity
- (2018) Lars Michel et al. Journal of Thoracic Disease
- Comparison of long-term outcome in anthracycline-related versus idiopathic dilated cardiomyopathy: a single centre experience
- (2017) Alessandra Fornaro et al. EUROPEAN JOURNAL OF HEART FAILURE
- The continuing evolution of cardiac troponin I biomarker analysis: from protein to proteoform
- (2017) Daniel Soetkamp et al. Expert Review of Proteomics
- Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy
- (2017) Dimitrios Zardavas et al. JOURNAL OF CLINICAL ONCOLOGY
- The Role of Biomarkers in Detection of Cardio-toxicity
- (2017) Kevin S. Shah et al. Current Oncology Reports
- High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury
- (2017) Melissa Jones et al. ANNALS OF CLINICAL BIOCHEMISTRY
- Are Biomarkers Predictive of Anthracycline-Induced Cardiac Dysfunction?
- (2016) Abhidha Malik et al. Asian Pacific Journal of Cancer Prevention
- 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
- (2016) Jose Luis Zamorano et al. EUROPEAN HEART JOURNAL
- Troponin and exercise
- (2016) T. Gresslien et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Biomarkers as Predictors of Cardiac Toxicity From Targeted Cancer Therapies
- (2016) Ronald M. Witteles JOURNAL OF CARDIAC FAILURE
- Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
- (2016) Anthony F. Yu et al. ONCOLOGIST
- Roadmap for biomarkers of cancer therapy cardiotoxicity
- (2015) Anthony F Yu et al. HEART
- Cardiotoxicity due to Chemotherapy: the Role of Biomarkers
- (2015) Patrick L. Stevens et al. Current Cardiology Reports
- Biomarkers for the early detection of anthracycline-induced cardiotoxicity: current status
- (2014) Jan M. Horacek et al. BIOMEDICAL PAPERS-OLOMOUC
- “Troponin Elevation in Coronary Ischemia and Necrosis”
- (2014) Stefan Agewall et al. Current Atherosclerosis Reports
- Cardiac Troponins: Bench to Bedside Interpretation in Cardiac Disease
- (2013) Vasundhara Muthu et al. AMERICAN JOURNAL OF THE MEDICAL SCIENCES
- Cardiac Troponin T and NT-proBNP as Biomarkers of Early Myocardial Damage in Amitriptyline-Induced Cardiovascular Toxicity in Rats
- (2013) Victorita Sorodoc et al. INTERNATIONAL JOURNAL OF TOXICOLOGY
- Early Increases in Multiple Biomarkers Predict Subsequent Cardiotoxicity in Patients With Breast Cancer Treated With Doxorubicin, Taxanes, and Trastuzumab
- (2013) Bonnie Ky et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study
- (2012) Adedayo A. Onitilo et al. BREAST CANCER RESEARCH AND TREATMENT
- Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab
- (2012) Heloisa Sawaya et al. Circulation-Cardiovascular Imaging
- Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib
- (2011) P. G. Morris et al. CLINICAL CANCER RESEARCH
- The Utility of Cardiac Biomarkers, Tissue Velocity and Strain Imaging, and Cardiac Magnetic Resonance Imaging in Predicting Early Left Ventricular Dysfunction in Patients With Human Epidermal Growth Factor Receptor II–Positive Breast Cancer Treated With Adjuvant Trastuzumab Therapy
- (2011) Nazanin Fallah-Rad et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trials
- (2010) Stephane Ederhy et al. INVESTIGATIONAL NEW DRUGS
- Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation
- (2010) Daniela Cardinale et al. JOURNAL OF CLINICAL ONCOLOGY
- Anthracycline-Induced Cardiomyopathy
- (2010) Daniela Cardinale et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Role of Biomarkers in Chemotherapy-Induced Cardiotoxicity
- (2010) Daniela Cardinale et al. PROGRESS IN CARDIOVASCULAR DISEASES
- Cardiac troponin may be released by ischemia alone, without necrosis
- (2009) Peter E. Hickman et al. CLINICA CHIMICA ACTA
- Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: Effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide
- (2009) Mauro Feola et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Cardiac Troponin I Seems to Be Superior to Cardiac Troponin T in the Early Detection of Cardiac Injury Associated with Anthracycline Treatment
- (2008) Jan M. Horacek et al. ONKOLOGIE
- Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity
- (2007) Peter James O’Brien TOXICOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search